Last update Oct. 30, 2023

Alefacept

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Alefacept is a recombinant human fusion protein that binds to CD2 on memory T cells, preventing their activation and reducing their number. It is used in the treatment of moderate to severe chronic plaque psoriasis. Intramuscular administration one dose per week for 12 weeks. 

At the time of the last update, we found no published data on its excretion in breast milk.

Its high molecular weight makes it unlikely to pass into breast milk.

Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed.

Alternatives

We do not have alternatives for Alefacept.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Alefacept in other languages or writings:

Group

Alefacept belongs to this group or family:

Tradenames

Main tradenames from several countries containing Alefacept in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 51.801 daltons
VD 0.1- 0.17 l/Kg
Tmax 0.5 hours
270 hours

References

  1. Astellas Ph. Alefaceft. Drug Summary. 2006 Full text (in our servers)
  2. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002 Abstract

Total visits

3,028

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM